Days after a Chinese researcher incensed the world of science with claims of editing the genomes of twin girls, an American company is plotting a CRISPR trial of its own. But in place of the secrecy and stagecraft that marked the Chinese experiment, Editas Medicine (EDIT) went the old-fashioned way: waiting for approval from the Food and Drug Administration.
The company, headquartered in Cambridge, Mass., got the FDA’s blessing to test a CRISPR-based therapy on patients with a rare genetic disorder that leads to blindness. Editas, which is partnered with Botox maker Allergan (AGN), said it plans to enroll between 10 and 20 patients in a study to test the treatment’s safety and efficacy.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
It is a great news for the company and patients!! FDA has done its job!! However, there are more to do!! About 80 genes could cause multiple cancers in lots of families; gene therapy in germline or embryo is necessary!!
Gene editing of the germline is bad business for pharma companies. You can’t sell cures if there are no ill patients